search

Active clinical trials for "Rosacea"

Results 51-60 of 196

To Evaluate the Therapeutic Equivalence and Safety in Treatment of Moderate Facial Rosacea

Rosacea

To demonstrate the superiority of the efficacy of the test and reference products over that of the placebo control in the treatment of moderate facial rosacea.

Completed4 enrollment criteria

Treatment of Dilated Blood Vessels on the Cheeks With a New Yellow Laser and a Traditional Green...

TelangiectasiaRosacea

The goal is to compare a novel yellow laser, based on semiconductor technology, with traditional green laser, in the treatment of cheek telangiectasias. The trial design is randomized split-face double-blinded study with 20-30 volunteers. The improvement will be assessed using a 7-point Telangiectasia Grading Scale.

Completed10 enrollment criteria

Clinical Endpoint Study of Ivermectin 1% Cream

Moderate to Severe Papulopustular Rosacea

A randomized, double-blind, placebo-controlled, parallel-design, multiple-site clinical study to evaluate the therapeutic equivalence and safety of ivermectin cream 1% (Actavis Laboratories UT, Inc.) to SoolantraTM (ivermectin) cream 1% (Galderma) in the treatment of moderate to severe papulopustular rosacea.

Completed38 enrollment criteria

A Study to Assess the Efficacy, Safety and Tolerability of DFD-04

Rosacea

The purpose of this exploratory study is to assess the efficacy, safety and tolerability of DFD-04 Ointment for topical treatment of rosacea over 12 weeks of treatment.

Completed28 enrollment criteria

Topical Mitogenic-Activated Protein Kinase (MAPK) Inhibition in Rosacea

RosaceaErythematotelangiectatic

This is a prospective, vehicle controlled, double blinded study to evaluate the safety and potential efficacy of a topical formulation of a MEK inhibitor in patients with erythematotelangiectatic rosacea

Completed6 enrollment criteria

A Randomized, Double-Blind Study to Assess the Safety, Efficacy and Tolerability of Oral DFD-29...

Papulopustular Rosacea

This is a 16-week, multicenter, randomized, parallel-group, double-blind, controlled study. After assessing eligibility during a screening period of up to 30 days, approximately 320 subjects at least 18 years old who are diagnosed with moderate to severe papulopustular rosacea will be randomized in a 3:3:2 ratio to DFD-29 (40 mg), Doxycycline capsules 40 mg, or Placebo once daily for 16 weeks.

Completed13 enrollment criteria

Study to Evaluate the Safety and Efficacy of a Once-Daily CLS001 Topical Gel Versus Vehicle

Rosacea

This study evaluates the safety and efficacy of once-daily application of CLS001 topical gel compared to vehicle gel in subjects with severe papulopustular rosacea.

Completed8 enrollment criteria

A Study to Evaluate the Safety and Clinical Study of Azelaic Acid Gel 15% in Patients With Moderate...

Rosacea

The purpose of the study is to compare the safety and efficacy profiles of a generic Azelaic Acid Gel, 15% to the reference listed Finacea® (azelaic acid) Gel, 15% in the treatment of moderate facial rosacea.

Completed39 enrollment criteria

A Study to Evaluate the Safety, Tolerability, and Effects of Anatabloc® Crème in Rosacea

Rosacea

This is a multi-site, four-visit, eight-week, double-blind, randomized, vehicle-controlled, parallel-group study followed by an eight-week open-label extension to evaluate the safety, tolerability, and potential effects of Anatabloc Facial Cream. The secondary aim is to evaluate if Anatabloc Facial Cream improves the appearance of the skin in subjects with mild to moderate rosacea.

Completed7 enrollment criteria

Phase 3 Efficacy and Safety Study of CD07805/47 Topical Gel in Subjects With Facial Erythema of...

Rosacea

Phase 3 efficacy and safety study of CD07805/47 topical gel in subjects with facial erythema associated with rosacea. The study hypothesis is that CD07805/47 gel, applied topically once daily is more efficacious than vehicle and provides an acceptable safety profile in the treatment of facial erythema associated with rosacea

Completed11 enrollment criteria
1...567...20

Need Help? Contact our team!


We'll reach out to this number within 24 hrs